Company profile
Phenotypeca Limited
Phenotypeca
Phenotypeca Limited is a UK company with status active founded in 2018 based in East Midlands.
Corporate ownership
Updated 06 Jun 2026 16:52
Company events
Reference milestones and recent Companies House filing stream events.
Accounts due
Accounts DueNext accounts due date
Confirmation statement due
Confirmation DueNext confirmation statement due date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Capital Allotment Shares
CapitalSH01 | Transaction MzQ1NjAwNjI1M2FkaXF6a2N4
Published 21 Feb 2025 05:06
Incorporated
InceptionCompany registered at Companies House
Spinout profile
Company description
Phenotypeca produces bakers yeast strains for the use in biotechnology processes.
Phenotypeca provides novel biologics production strains of the regulatory friendly baker's yeast, Saccharomyces cerevisiae for the manufacture of biologicals. We offer world leading yeast technology to rapidly provide cost-effective production strains optimised for specific biotechnology processes. This is achieved by harnessing the natural diversity in up to a billion different yeast cells to identify those with the ideal phenotypes and performance characteristics for industrial process conditions. Working with our customers we aim to improve access to life-saving medicines and promote sustainable manufacturing. With baker's yeast now fully established for the safe and economic production of FDA approved biologics, such as insulins and vaccines, our technology is ideal for taking bioprocesses to the next level.
Project impact
As a recent startup there is limited impact at the moment. There are 6 salaried employees, one full time research scientist, a scientific officer, a research director, business director and tech support. An Innovate UK award for proof of principle was awarded in January 2020 which subcontracts some work to the University lab in Leicester.
Public funding
Projects
PhenoDev: A novel Saccharomyces cerevisiae platform for high-yield protein secretion
1 Oct 2021 to 31 Jan 2023
Recombinant therapeutic proteins and many vaccines are costly to manufacture. Current state-of-the-art protein expression systems include: * Mammalian Chinese Hamster Ovary (CHO) and HEK293 systems. _Limitations:_ Slow-growing cells, expensive media, high energy burden (e.g., for supplying CO2, and for heating the cell cultures), high environmental burden...
The development of yeast strains to produce SARS-CoV-2 antigens for serological assays enabling the detection of COVID-19 cases in the UK population
1 Jun 2020 to 31 Mar 2021
Phenotypeca Ltd is a biotechnology company based in the University of Nottingham's Synthetic Biology Research Centre developing next-generation yeast for the manufacture of recombinant proteins, such as biopharmaceuticals. Using a genetically diverse collection of natural baker's yeast engineered for large-scale industrial processes we breed up to a billi...
Development of second-generation S. cerevisiae hosts for enhanced protein yield and quality
1 Jan 2020 to 30 Sep 2021
Recombinant protein expression is the keystone manufacturing technique supporting production of many biological therapies. A large number of protein expression systems exist, but the majority of biological drugs and protein products that are approved for clinical use have been manufactured using mammalian cell culture techniques. These manufacturing proce...